TEF-4 Antibody (404C5a): sc-81397

TEF-4 Antibody (404C5a) is a mouse monoclonal IgG1 antibody that detects TEF-4 protein of human origin by western blotting (WB) and immunoprecipitation (IP). TEF-4 (404C5a) antibody is available as a non-conjugated anti-TEF-4 antibody. The transcriptional enhancer factor (TEF)/TEAD family, which includes TEF-1, TEF-3, TEF-4, and TEF-5, is characterized by a highly conserved 68-amino acid TEA/ATTS DNA-binding domain that interacts with specific enhancers such as SV40 GT-IIC (GGAATG) and muscle-specific M-CAT (GGTATG). TEF-4 plays a crucial role in cellular processes, being strongly coexpressed with TEF-1 in mouse mitotic neuroblasts and also found in the gut and nephrogenic region of the kidney. TEF-4 is essential for mediating mitogenic signals through association with transcriptional coactivator YAP65, which enhances cellular proliferation. Furthermore, TEF-4 is involved in activating CTP:phosphocholine cytidylyltransferase (CCT) alpha, the rate-limiting enzyme in phosphatidylcholine biosynthesis, by boosting transcriptional activity of Ets-1. The ability of TEF-4 to regulate these critical pathways underscores its importance in development and cellular function, making anti-TEF-4 antibody (404C5a) a valuable tool for researchers studying gene expression and signaling mechanisms in human cells.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

TEF-4 Antibody (404C5a) References:

1. Cooperative binding of TEF-1 to repeated GGAATG-related consensus elements with restricted spatial separation and orientation.  |  Jiang, SW., et al. 2000. DNA Cell Biol. 19: 507-14. PMID: 10975468
2. Identification of transcriptional enhancer factor-4 as a transcriptional modulator of CTP:phosphocholine cytidylyltransferase alpha.  |  Sugimoto, H., et al. 2001. J Biol Chem. 276: 12338-44. PMID: 11279002
3. TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm.  |  Vassilev, A., et al. 2001. Genes Dev. 15: 1229-41. PMID: 11358867
4. Identification of Ets-1 as an important transcriptional activator of CTP:phosphocholine cytidylyltransferase alpha in COS-7 cells and co-activation with transcriptional enhancer factor-4.  |  Sugimoto, H., et al. 2003. J Biol Chem. 278: 19716-22. PMID: 12642588
5. An evolutionary, structural and functional overview of the mammalian TEAD1 and TEAD2 transcription factors.  |  Landin-Malt, A., et al. 2016. Gene. 591: 292-303. PMID: 27421669
6. Exploring TEAD2 as a drug target for therapeutic intervention of cancer: A multi-computational case study.  |  Pal, R., et al. 2021. Brief Bioinform. 22: PMID: 33611407
7. A Therapeutically Targetable TAZ-TEAD2 Pathway Drives the Growth of Hepatocellular Carcinoma via ANLN and KIF23.  |  Saito, Y., et al. 2023. Gastroenterology. 164: 1279-1292. PMID: 36894036
8. A TEAD2-Driven Endothelial-Like Program Shapes Basal-Like Differentiation and Metastasis of Pancreatic Cancer.  |  Yoo, HB., et al. 2023. Gastroenterology. 165: 133-148.e17. PMID: 36907523
9. TEAD2 Promotes Hepatocellular Carcinoma Development and Sorafenib Resistance via TAK1 Transcriptional Activation.  |  Zhang, Y., et al. 2024. Mol Cancer Res. 22: 1102-1116. PMID: 39106149
10. EGF/EGFR-YAP1/TEAD2 signaling upregulates STIM1 in vemurafenib resistant melanoma cells.  |  Bai, W., et al. 2024. FEBS J. 291: 4969-4983. PMID: 39298503
11. A novel family of developmentally regulated mammalian transcription factors containing the TEA/ATTS DNA binding domain.  |  Jacquemin, P., et al. 1996. J Biol Chem. 271: 21775-85. PMID: 8702974
12. Localization of human transcription factor TEF-4 and TEF-5 (TEAD2, TEAD3) genes to chromosomes 19q13.3 and 6p21.2 using fluorescence in situ hybridization and radiation hybrid analysis.  |  Jacquemin, P., et al. 1999. Genomics. 55: 127-9. PMID: 9889009

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-TEF-4 Antibody (404C5a) has 2 citations in a variety of scientific publications.

Primary antibodies like Anti-TEF-4 Antibody (404C5a) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

TEF-4 Antibody (404C5a) Specifications

Alternate Product Name: TEF-4

Product Clone Name: 404C5a

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁

Amino Acids:

Epitope Target: TEF-4

Epitope Species: human

Product Reactivity/Detection: TEF-4

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP

Vialing Information: Each vial contains 100 µg IgG₁ in 1.0 ml of PBS with < 0.1% sodium azide and 1.0% stabilizer protein

Research Citations: 2 citations in various scientific publications

Available Conjugates/Forms for TEF-4 Antibody (404C5a): N/A

The preferred TEF-4 antibody is TEF-4 Antibody (C-10): sc-518181.